OGXI : Analysis & Opinions

  1. OncoGenex's AFFINITY on Track, Passes Futility Analysis - Analyst ...

    January 19, 2015
    OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the phase III AFFINITY study on custirsen has passed the interim futility ...
  2. OncoGenex to End Deal with Teva & Regain Custirsen Rights - Analyst ...

    December 31, 2014
    OncoGenex Pharmaceuticals, Inc. (OGXI) executed an initial agreement to regain all rights to custirsen from Teva and end ...
  3. OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst ...

    December 17, 2014
    OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously ...
  4. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  5. Four High-Flying Pharmaceutical Companies

    October 28, 2009
    A look at some of the best-performing stocks year to date - up anywhere from 400% to 2000%.
Trading Center